Healthpeak Properties, Inc. (DOC)
Bienes raíces — REIT de salud
Healthpeak Properties is a diversified healthcare real estate REIT — medical outpatient buildings, life sciences lab space, and senior housing under RIDEA structures — trading near 52-week lows as occupancy in its lab segment falls sharply on properties in relaunch. FY2026 adjusted FFO guidance marks a year-over-year trough of approximately 8%, with gradual recovery from 2027 supported by senior housing strength and medical outpatient stabilization. The base case leaves it Undervalued, with an estimated total return of +13% over five years and a current dividend yield near 6%, sustained by a payout below 100% of AFFO.
- Price
- $21.69
- Intrinsic value (5y, base)
- $31
- Total annual return (5y)
- 12.5%
- Status (nominal)
- Undervalued
- Margin of safety
- +29%
The essentials
- Portfolio of 689 healthcare real estate properties: medical outpatient (46% of adjusted NOI), lab (37%), and senior housing (11%), with the remainder in loans and non-reportable assets
- The lab segment is going through an occupancy trough (88.2% versus 97.5% a year earlier) that is dragging down 2026 adjusted FFO guidance; senior housing is growing comparable net operating income at a high single/double digit rate under RIDEA structures
- Monthly dividend of US$1.224 annualized, with a payout on AFFO near 70% that leaves room for growth once adjusted FFO recovers from the trough guided for 2026
Intrinsic value — two valuation methods
Total return at 5 years: 12.6%/year = 7.3% appreciation + 5.2% dividend. The target price ($31) is ex-dividend; the $6 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $42 · Multiples $30) exceeds the market price ($22).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $22 trades ~28.9% below its value discounted to today (~$30); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — Infravalorado: the target price ($31) plus dividends yield above the required average return (10%) — the business compounds.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$20.
Thesis
The business
Healthpeak Properties combines three healthcare real estate businesses with distinct dynamics: medical outpatient and lab, mostly leased triple-net to hospital systems and life sciences companies, and senior housing, operated under RIDEA structures where the company assumes direct operating risk. The moat is narrow in width and eroding in trend: facility specialization and hospital affiliation protect rent pricing — lab rent per square foot kept rising despite the occupancy decline — but do not prevent scientific oversupply from eroding the segment's aggregate occupancy (from 97.5% to 88.2% in one year). Senior housing is the counterweight, with double-digit comparable net operating income growth.
The valuation
Valued as a single piece at the equity level, by adjusted P/FFO on the aggregate terminal metric (reit band 15-20x), because the three lines share a REIT capital structure, funding, and a common shareholder base, and the filing does not allow debt or invested capital to be separated by segment with the precision needed for an independent EV bridge. The stock trades at 13× of adjusted FFO today, compressing to 12× in five years if the base case plays out; the exit multiple is set near the floor of the band because the moat is eroding in lab and the return on invested capital (ROIC ~3.1%) is far below the 10% bar. The base case leaves it Undervalued, with a five-year value of $31 per share.
The margin of safety
It trades at a real discount to value, though short of the required margin of safety., with an estimated total return of +13% over five years combining price appreciation and a current dividend yield near 6%, sustained by a payout on AFFO near 70%. Today's margin of safety is -10% against the maximum price derived from the 15% annual hurdle — the expected return depends more on the recovery of adjusted FFO than on multiple expansion, which stays near the floor of the reit band even in the base case.
What to watch
The central disconfirming factor for the thesis is whether lab occupancy fails to recover at the pace assumed in FY2026 guidance and the base case: in that scenario, the adverse case — with a multiple compressed to the floor of the band and a slower adjusted FFO path — better describes the outcome. Additional risks to monitor: cuts to Medicaid or Medicare site-neutral payments affecting medical outpatient, the direct operating risk the company assumes under senior housing's RIDEA structures, and whether the Janus Living spin-off closes on the expected terms and timeline.
Educational / informational. Does not constitute investment advice.